The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer.

There is limited data regarding the added benefit of adjuvant systemic therapy in the management of small, node-negative, HER2+ breast cancer. In a multi-institutional retrospective analysis using the American Society of Clinical Oncology CancerLinQ database, we compared survival outcomes among T1a-c N0 HER2+ patients diagnosed between 2010 to 2021 who received locoregional therapy alone or in combination with adjuvant trastuzumab (+/- chemotherapy). Primary outcomes were invasive disease-free survival (iDFS) and overall survival (OS). Of the 1,184 patients, 436 received locoregional therapy alone. We found a statistically significant improvement in iDFS (HR 0.73, P = 0.003) and OS (HR 0.63, P = 0.023) on univariate analysis with adjuvant trastuzumab with or without chemotherapy which remained statistically significant on multivariate analysis. Three-arm univariate analysis found that iDFS was significantly improved with trastuzumab monotherapy (P = 0.003) and combination therapy (P = 0.027) compared to observation. Subgroup data suggests that T1b/c tumors derive the greatest benefit.

nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.

In patients with locally advanced human papillomavirus (HPV)-unrelated head and neck squamous-cell carcinoma (HNSCC), cisplatin and radiation therapy (CisRT) resulted in a local-regional recurrence (LRR) rate of 35%, progression-free survival (PFS) of 49%, and overall survival (OS) of 60%. We, and others, showed that nab-paclitaxel is an active agent in metastatic and locally advanced HNSCC. The aim of this report was to assess the efficacy of nab-paclitaxel-based induction chemotherapy and CisRT in HPV-unrelated HNSCC. We performed a retrospective single-institution analysis of patients treated with nab-paclitaxel-based chemotherapy and CisRT. Key inclusion criteria included stage III-IV HPV-unrelated HNSCC. Induction chemotherapy included nab-paclitaxel and cisplatin (AP), AP + 5-fluorouracil (APF), or APF + Cetuximab (APF-C). Endpoints included LRR, overall relapse, PFS, and OS. Thirty-eight patients were the subject of this analysis. Patient characteristics included median age 59 years (IQR: 54-64) and smoking history in 36 patients (95%). Primary tumor sites included larynx/hypopharynx (27), p16 negative oropharynx (10), and oral cavity (1). Most patients had bulky disease: 82% T3-4 (n = 31) and 74% N2b-3 (n = 28). Median follow-up was 44 months (IQR: 23-59). The three-year LRR rate was 16% (95% confidence interval [CI] 7-34) and the overall relapse rate was 22% (95% CI 11-41). The three-year PFS was 64% (95% CI 46-77) and OS was 72% (95% CI 54-84). Among patients with HPV-unrelated HNSCC, nab-paclitaxel-based induction chemotherapy and CisRT resulted in a lower-than-expected rate of LRR and more favorable PFS and OS compared to historical results with CisRT.

Microgel-based etalon coated quartz crystal microbalances for detecting solution pH: The effect of Au overlayer thickness.

Poly (N-isopropylacrylamide)-co-acrylic acid (pNIPAm-co-AAc) microgels were "painted" on the Au electrode of a quartz crystal microbalance (QCM). Another Au layer (overlayer) was subsequently deposited on the microgel layer. This structure is known as a microgel-based etalon. These devices have been shown to exhibit optical properties (i.e., color) that depend on solution pH and temperature, among other things. Previously, we measured QCM frequency shifts that are a result of solution pH changes; the frequency shifts are a direct result of the pH dependent solvation state of the microgels that make up the etalon. In fact, the shifts observed for the etalons were much greater in magnitude than just a microgel layer immobilized on the QCM crystal without the Au overlayer. We reasoned that the Au overlayer lead to an enhancement of the observed frequency change due to its mass. In this submission we investigate how the Au overlayer thickness (mass) affects the observed sensitivity to solution pH. We found that the change in QCM resonant frequency depended dramatically on the mass of the Au overlayer.

Detecting solution pH changes using poly (N-isopropylacrylamide)-co-acrylic acid microgel-based etalon modified quartz crystal microbalances.

Poly (N-isopropylacrylamide)-co-acrylic acid (pNIPAm-co-AAc) microgel-based etalons have been shown to have visible color and unique spectral properties, which both depend on solution temperature and pH. In this investigation, pNIPAm-co-AAc microgel-based etalons were fabricated on the Au electrode of a quartz crystal microbalance (QCM), and the resonant frequency of the QCM monitored as a function of temperature, at pH 3.0. Furthermore, the resonant frequency at either pH 3.0 or 7.0 was monitored while keeping the solution temperature constant at various temperatures. In all cases, when the solution temperature was below the collapse transition for the microgels (∼32°C), the resonant frequency at pH 3.0 was lower than at pH 7.0, which we attribute to the film transitioning from a deswollen to swollen state, respectively. It was observed that the magnitude of the resonant frequency change increased as the solution temperature approached the collapse temperature for the microgels. The overall sensitivity to pH was determined to be 1.3×10(-8)M [H(+)]Hz(-1) and a theoretical detection limit of 390nM was obtained. This sensitivity will be exploited further for future biosensing applications.